2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183889
    p-Ethoxychrysoidin 94-10-0 98%
    p-Ethoxychrysoidin is a benzotriazole-based NLRP3 inhibitor. p-Ethoxychrysoidin can be used in research on inflammatory diseases and neurodegenerative diseases.
    p-Ethoxychrysoidin
  • HY-183918
    Amfenac ethyl ester 61941-57-9 98%
    Amfenac ethyl ester is an orally active cyclooxygenase (COX) inhibitor. Amfenac ethyl ester exhibits antiinflammatory activity in rodent models. Amfenac ethyl ester can be used for the research of inflammation.
    Amfenac ethyl ester
  • HY-183921
    SQ 32547 135100-65-1
    SQ 32547 is a dihydropyridine calcium channel inhibitor with antihypertensive and anti-ischemic activities. SQ 32547 modulates sarcolemmal voltage-dependent calcium channels to inhibit calcium influx, and exerts direct anti-ischemic activity by suppressing myocardial contracture formation and reducing lactate dehydrogenase (LDH) release. SQ 32547 can be used in research related to hypertension, angina pectoris and neurogenic inflammation.
    SQ 32547
  • HY-183923
    SX 3202 147254-65-7
    SX 3202 is an aldose reductase inhibitor. SX 3202 can be used for the research of diabetic complications.
    SX 3202
  • HY-183924
    SYK-IN-14 725237-11-6 98%
    SYK-IN-14 is an orally active Syk and ZAP-70 inhibitor with human Syk IC50 of 0.006 μM, human ZAP-70 IC50 of 0.23 μM. SYK-IN-14 functionally inhibits Syk kinase activity in vitro. SYK-IN-14 functionally inhibits ZAP-70 kinase activity in vitro. SYK-IN-14 suppresses passive cutaneous anaphylaxis reaction in Mus musculus mice. SYK-IN-14 suppresses Concanavalin A (HY-P2149)-induced IL-2 production in Mus musculus mice. SYK-IN-14 can be used for the research of allergic disorders and autoimmune diseases.
    SYK-IN-14
  • HY-183932
    NPC-14695 146561-59-3 98%
    NPC-14695 is a competitive and selective M3 muscarinic receptor antagonist, with a Kd value of 15 nM for guinea pig M3, 60 nM for guinea pig M2, and 25 nM for rabbit M1. NPC-14695 exhibits higher activity towards M3 receptors in bronchial smooth muscle than towards those regulating salivary secretion. NPC-14695 inhibits Carbachol (HY-B1208)-induced contraction of isolated rabbit iris smooth muscle.
    NPC-14695
  • HY-183955
    GNF7156 2041071-54-7
    GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes.
    GNF7156
  • HY-183973
    MTXPG5 80801-54-3 98%
    MTXPG5 is a long-chain Methotrexate (HY-14519) metabolite and thymidylate synthase inhibitor with a Ki of 0.047 μM. MTXPG5 inhibits 5-aminoimidazole-4-carboxamide ribonucleotide transformylase, interferes with DNA synthesis and immune cell proliferation, and inhibits pro-inflammatory cytokine production via extracellular adenosine accumulation and elevated cAMP levels. MTXPG5 can be used for the research of leukaemia and rheumatoid arthritis.
    MTXPG5
  • HY-185047
    Fluticasone propionate O-diphosphoethanolamine 1815577-95-7
    Telisotuzumab Adizutecan is a drug intermediate that can be used for the synthesis of Fluticasone (HY-B0603).
    Fluticasone propionate O-diphosphoethanolamine
  • HY-185099
    N-Demethy EM-163 1206480-92-3
    N-Demethy EM-163 is a drug intermediate that can be used in the synthesis of EM-163 (HY-163035).
    N-Demethy EM-163
  • HY-185150
    PMEG 114088-58-3 98%
    PMEG is a nuclear DNA polymerases α, δ, and ε inhibitor that causes DNA chain termination, inhibits DNA synthesis, induces cytotoxicity in dividing cells. PMEG is an acyclic nucleotide phosphonate that forms an active phosphorylated metabolite, PMEG diphosphate, within cells. PMEG has activity against leukemia and melanoma in rodent models. PMEG has poor cell permeability; its prodrug is Rabacfosadine (GS-9219) (HY-13640). PMEG shows antiviral activity against against various DNA virus infections including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). PMEG can be used for the research of non-hodgkin's lymphoma[1][2].
    PMEG
  • HY-185172
    PDE4-IN precursor 2750575-21-2 98%
    PDE4-IN precursor (Compound 10) is an orally active prodrug of phosphodiesterase 4 (PDE4) inhibitor. PDE4-IN precursor undergoes enzymatic hydrolysis in the colon to release the active PDE4 inhibitor, which exerts local anti-inflammatory effects on the colonic mucosa. PDE4-IN precursor is applicable to research related to ulcerative colitis, Crohn's disease, and other relevant conditions.
    PDE4-IN precursor
  • HY-185299
    CCR2 antagonist 6 1421063-89-9
    CCR2 antagonist 6 (Example 98) is a CCR2 antagonist (Kb: 0.215 μM for CCR2, 0.174 μM for hCCR2B). CCR2 antagonist 6 can be used in the research of inflammation and autoimmune diseases.
    CCR2 antagonist 6
  • HY-185463
    β-Tryptase-IN-1 725228-46-6 98%
    β-Tryptase-IN-1 is a selective β-tryptase inhibitor with a Ki of 10 nM. β-Tryptase-IN-1 binds to the inducible S4+ pocket unique to β-tryptase. β-Tryptase-IN-1 can be used for the researches of asthma and chronic obstructive pulmonary disease (COPD).
    β-Tryptase-IN-1
  • HY-186003
    CCR9 modulator-1 1111300-51-6
    CCR9 modulator-1 (example 16) is a CCR9 modulator.
    CCR9 modulator-1
  • HY-186007
    KLK7 modulator-1 342594-95-0
    KLK7 modulator-1 is a KLK7 modulator.
    KLK7 modulator-1
  • HY-186107
    ZY36
    ZY36 is a SaClpP agonist with an EC50 of 1.01 μM against Staphylococcus aureus. ZY36 activates SaClpP-mediated proteolysis. ZY36 inhibits the growth of Staphylococcus aureus. ZY36 is applicable to studies related to Staphylococcus aureus infections, such as peritonitis.
    ZY36
  • HY-186108
    ZY38
    ZY38 is a SaClpP agonist that activates SaClpP-mediated α-casein hydrolysis with an EC50 of 1.52 μM. ZY38 exhibits bactericidal activity against Staphylococcus aureus. ZY38 is applicable to studies related to Staphylococcus aureus infections, such as peritonitis.
    ZY38
  • HY-186199
    α-Glucosidase-IN-117 2410538-77-9
    α-Glucosidase-IN-117 is a low-activity α-glucosidase (α-glucosidase) inhibitor belonging to the coumarin derivative class, with an inhibition rate of 19.51% at 100 μM. α-Glucosidase-IN-117 can be used in diabetes research.
    α-Glucosidase-IN-117
  • HY-18620R
    DZ2002 (Standard) 33231-14-0
    DZ2002 (Standard) is the analytical standard of DZ2002. This product is intended for research and analytical applications. DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis.
    DZ2002 (Standard)
Cat. No. Product Name / Synonyms Application Reactivity